Securities code: 002907 securities abbreviation: Chongqing Pharscin Pharmaceutical Co.Ltd(002907) Announcement No.: 2022-005 bond Code: 128069 bond abbreviation: Huasen convertible bond
Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
About the change of the company’s drug production license and the completion of related products
Announcement on the filing of domestically produced drugs
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Chongqing Pharscin Pharmaceutical Co.Ltd(002907) (hereinafter referred to as “the company”) recently received the drug production license (license No.: Yu 20150018) issued by Chongqing drug administration. This time mainly involves the change of the production site of orlistat capsule (gyzz: h20103180). At the same time, the product has been filed and publicized on the official website of the State Drug Administration. The details are as follows:
1、 Change of drug production license
(I) changes
The production site of orlistat capsule (gyzz: h20103180) is changed to: capsule production line of workshop 1, industrial park, Rongchang District, Chongqing; Hard capsule production line of workshop 503, No. 143, Banqiao Road, Changzhou street, Rongchang District, Chongqing.
Other contents remain unchanged******
(II) specific contents of the changed drug production license
Enterprise name: Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
License No.: Yu 20150018
Social Credit Code: 915002262038944463
Category code: ahyzbhzchdh
Registered address: Industrial Park, Rongchang District, Chongqing
Legal representative: you Hongtao
Person in charge of the enterprise: you Hongtao
Quality Director: Deng Lin
Quality authorized person: Wang Qian
Production leader: Zhou Bangjian
Valid until: November 9, 2025
Production address and scope: Rongchang District Industrial Park, Chongqing: soft capsule, lyophilized powder injection, powder injection, small volume injection, API, granule, powder, tablet, hard capsule, pretreatment and extraction of traditional Chinese medicine, inhalation solution***
No. 143, Banqiao Road, Changzhou street, Rongchang District, Chongqing: powder injection, freeze-dried powder injection, tablet, hard capsule, soft capsule, granule, powder, pretreatment and extraction of traditional Chinese medicine, decoction pieces of traditional Chinese medicine, drops (capsule)***
2、 Registration information of domestically produced drugs
(I) basic information of drugs
Generic name of drug: orlistat capsule
Record No.: Yu Bei 2022001125
Drug approval No.: gyzz h20103180
Listing Permit Holder: Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
Address of listing Permit Holder: Industrial Park, Rongchang District, Chongqing
Name of manufacturer: Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
Address of manufacturer: Banqiao, Changzhou street, Rongchang District, Chongqing
143 Road
Filing content: update the drug registration approval document due to the change of drug production license
Name or address of the manufacturer.
Filing authority: Chongqing Drug Administration
Filing date: January 11, 2022
(II) other relevant information of drugs
Orlistat capsule: used for the treatment of obese or overweight patients (body mass index ≥ 24).
3、 Impact on the company and risk tips
The change of drug production license and the resulting change of drug filing information are conducive to the large-scale production of products and form a large-scale effect. At the same time, it is conducive to the production and supply of the company’s own brand (Quchang) orlistat capsule, so as to better meet the market demand.
The above changes and filing have no significant impact on the company’s performance in the short term. Please pay attention to the investment risks. 4、 Document for future reference (I) drug production license (license No.: Yu 20150018). It is hereby announced
Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
Board of directors
January 13, 2022
